Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 1, 2007

Abraxis BioScience Acquires Manufacturing Facility from Watson Pharmaceuticals

  • Abraxis BioScience acquired a sterile injectable Phoenix-based manufacturing plant from Watson Pharmaceuticals. The facility, which has the ability to produce lyophilized powders, suspension products, and aqueous and oil solutions, currently manufactures products for both Watson and other third parties.

    The facility is approximately 200,000 sq. ft. and includes manufacturing as well as chemistry and microbiology laboratories. Abraxis officials say that this plant, along with its manufacturing site located in Melrose Park, IL, will produce the company’s current and future products. This is expected to take place after completion of the planned separation of its product business—Abraxis Oncology and Abraxis Research (the new Abraxis BioScience)—from its hospital-based product business, Abraxis Pharmaceutical Products.

    Also, Abraxis will serve as a contract manufacturer for certain injectable products currently produced in this site for a specified period of time.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »